Molnupiravir

The trial with over 25,000 participants, however, suggests that patients taking molnupiravir recovered faster -- on average 4.2 days quicker -- compared to patients in the control group.

Divi’s Labs: Steady margin profile amid cost headwind

Earnings trigger for the medium term is Contrast Media API opportunity, where there is limited competition

Hetero finds positive results from Molnupiravir third phase trials

The trials showed that Molnupiravir reduced the risk of hospitalisation by over 65 percent compared to standard of care medication alone

Molnupiravir more effective against Omicron, claims new study

Even as the third wave of COVID-19 pandemic subsides in India and most cases are reported to be mild, a new study has said that Molnupiravir, granted regulatory approval in the country in December, 2021 can be useful for patients at risk of disease progression.

New antiviral drug combo highly effective against COVID-19: Study

The research, published recently in the journal Nature, suggests that these drugs are more potent when used in combination than individually.

Laurus Labs: Diversification away from ARVs on track

The share of the Laurus antiretroviral business in total is expected to be less than 1/3rd by 2025, compared to 50 percent now as the company’s other engines of growth gain traction

Dr Reddy’s: Supported by traction in limited competition products

Sales growth in North America was helped by healthy market share for the generic version of Vascepa

Natco Pharma gets non-exclusive licence to manufacture, sell anti-COVID pill Molnupiravir

The Indian Council of Medical Research has not included Molnupiravir in the clinical management protocol for COVID-19 despite the country's drug regulator granting emergency use nod.

Molnupiravir not included in COVID-19 treatment guidelines as its harms outweigh benefits : Health Ministry

The ministry said that after trials and discussions it has been found that Molnupiravir was not of much benefit in COVID treatment since the antiviral drug has risks and warrants caution in use and efforts should be made to restrict its use as the known and unknown harms far outweigh its claimed benefits.

Divi’s Lab: Green chemistry can set it apart

The management of Divi's Lab asserts that there are no Nitrosamine or Azido impurities in the company's Sartan API offerings.

Covid-19 | Molnupiravir shows more gains than risks, say experts

Health professionals treating coronavirus patients across the country reported that the Covid antiviral drug has reduced hospitalisation by 30 to 50 percent, as well as severity of the disease.

India to become hub for COVID-19 antiviral generic drugs: Fitch

Increased access to molnupiravir will keep hospitalisations and deaths in India to a manageable level as Omicron infections rise, Fitch Solutions said in a report.

Lupin launches Molnulup for COVID-19 treatment

Molnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 patients who have a high risk of progression of the disease, including hospitalisation.

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India

business,companies,coronavirus,COVID-19,Omicron,Aurobindo Pharma,Molnupiravir

Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment

With 10 capsules per strip, the total course of 40 capsules over 5 days would cost Rs 1,400, making it among the most affordable treatment options available to patients.

Emcure Pharmaceuticals to launch anti-Covid pill in week

The company plans to launch Molnupiravir under the brand name 'Lizuvira' in the Indian market.

Mankind, BDR Pharma join hands to launch anti COVID-19 pill Molulife

The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion, distribution is by Mankind Pharma, the company said in a statement.

Cipla gets EUA from DCGI to market Molnupiravir for COVID-19 treatment

The Mumbai-based firm said it plans to launch Molnupiravir under the brand name Cipmolnu.

Corbevax, Covovax, Molnupiravir approved for restricted emergency use against COVID-19

The announcement comes a day after the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) recommended granting emergency use authorisation (EUA) to the COVID-19 vaccines Covovax and Corbevax with certain conditions.

COVID-19: Is the hype around the oral drug Molnupiravir justified?

Molnupiravir increases our armamentarium against COVID-19, but it cannot replace vaccines. So, then what’s the hype all about? 

UK authorizes Merck antiviral pill, 1st shown to treat COVID-19

The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease.

Dr Reddy’s: Growth story remains intact; margins key monitorable

Dr Reddy's margins are likely to be weighed by recurring investments - digitization, brand building exercise & elevated R&D - in near to medium term

Sun Pharma: Traction in speciality likely to sustain

Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well

Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term

Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold

Lupin: Focus on inhalation and bio-similars to aid margins in medium term

In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets